Galectin Therapeutics (GALT) Total Current Liabilities (2010 - 2026)

Galectin Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 93.41% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 93.41% YoY), and the FY2025 full-year result was $8.0 million, down 77.32% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.3 million, down from $8.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $136.4 million in Q3 2025, with the low at $7.3 million in Q1 2026.
• Average Total Current Liabilities over 5 years is $26.6 million, with a median of $11.5 million recorded in 2023.
• Year-over-year, Total Current Liabilities surged 777.38% in 2025 and tumbled 93.41% in 2026.
• Tracing GALT's Total Current Liabilities over 5 years: stood at $13.0 million in 2022, then advanced by 20.47% to $15.7 million in 2023, then soared by 125.88% to $35.4 million in 2024, then plunged by 77.32% to $8.0 million in 2025, then fell by 9.0% to $7.3 million in 2026.
• The last three Total Current Liabilities figures came in at $7.3 million (Q1 2026), $8.0 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.

Peer Comparison